Buprenorphine
opioid used to treat opioid use disorder
Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It is administered under the tongue, in the cheek, by injection (intravenous or subcutaneous), or as a skin patch or implant. Maximum pain relief generally occurs within an hour and lasts up to 24 hours. In the United States, buprenorphine/naloxone (Suboxone) is usually prescribed to discourage injection misuse. Both formulations are Schedule III controlled substances.
Buprenorphine acts as an agonist, partial agonist, or antagonist at different opioid receptors. It relieves opioid withdrawal and reduces the effects of other opioids. Unlike full agonists such as heroin and methadone, it has a ceiling effect for some effects, including respiratory depression, but retains misuse potential.
Side effects include respiratory depression, sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction. It may increase seizure risk in susceptible people; opioid withdrawal after discontinuation is generally less severe than with other opioids.
“Buprenorphine” enters the record as opioid used to treat opioid use disorder. Crown Archives preserves that source wording while asking what Buprenorphine, opioid and used can confirm, complicate or overturn.
Why this record matters
“Buprenorphine” is worth following because a concise public description often conceals a longer documentary argument. Here, Buprenorphine, opioid and used provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Sep 16, 2026. The linked authority identifier is Q407721. The Library of Congress control number is sh85018028. None of the 1 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Buprenorphine”, its source revision and the description used here.
- Expand the search: follow Buprenorphine primary sources, Buprenorphine archive and Buprenorphine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Buprenorphine”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Buprenorphine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.